| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| aHIF | Human immunodeficiency virus type 1 (VSV-G-pseudotyped HIV-1 NL4-3) | MOI=Not provided;
72 hr |
Jurkat Human acute lymphoblastic leukemia cells | qPCR | 2 | Upregulation | p < 0.05 | Disease-related Human LncRNA Profiler (System Biosciences) | Not provided | 2013 | 23362321 |
| HIF1A-AS2 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 0.2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 10.45194838 | Upregulation | 0 | student's t test | 2020 | 32416070 | |
| HIF1A-AS2 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 3.529784238 | Upregulation | 4.51E-13 | student's t test | 2020 | 32416070 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose